Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5470757 | 1.00 | MAPT (0.59) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5475174 | 0.97 | MAPT (0.59) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5478093 | 0.97 | MAPT (0.59) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5477436 | 0.97 | MAPT (0.59) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5472042 | 0.91 | HSD11B1 (0.62) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5473219 | 0.91 | HSD11B1 (0.62) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5472049 | 0.91 | HSD11B1 (0.62) | MAPTMEN1KMT2AHSD11B1KDM4E | |
| SCHEMBL5476015 | 0.91 | HSD11B1 (0.66) | HSD11B1KDM4EALDH1A1POLB | |
| SCHEMBL5476020 | 0.91 | HSD11B1 (0.66) | HSD11B1KDM4EALDH1A1POLB | |
| SCHEMBL5474315 | 0.87 | HSD11B1 (0.68) | MEN1KMT2AHSD11B1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | ASTRAZENECA R&D ALDERLEY (GB) | 2007-05-17 | — | — | US | claimed |
| EP-1684757-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | AstraZeneca AB (SE) | 2006-08-02 | — | — | EP | claimed |
| WO-2005046685-A1 | SUBSTITUTED PIPERIDINES FOR THE TREATMENT OF METABOLIC SYNDROME | ASTRAZENECA AB (SE) | 2005-05-26 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070112000-A1 | Chemical compounds | HSD11B1, CYP11B1, HSD11B2 | MAPT 4016/4885MEN1 1206/4885KMT2A 2279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.